// App-Quantinova.ai

BSH19‐OR‐030 : HAVEN 2: Emicizumab Prophylaxis for Children with Haemophilia A with FVIII Inhibitors

Researchers

Presenter

  • G. Young

Principal Investigators

  • R. Liesner

  • R. Sidonio

  • J. Oldenburg

  • V. Jimenez-Yuste

  • J. Malangu

  • R. Kruse-Jarres

  • M. Wang

  • T. Chang

  • M. Uguen

  • M. Doral

  • C. Schmitt

  • G. Levy

  • M. Shima

  • M.E. Mancuso

Medical Centers

  • Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA

  • Great Ormond Street Hospital, London, United Kingdom

  • Emory University and Children's Healthcare of Atlanta, Atlanta, GA

  • University Hospital Bonn, Bonn, Germany

  • La Paz University Hospital, Madrid, Spain

  • University of Witwatersrand, Johannesburg, South Africa

  • Bloodworks Northwest, Seattle, WA

  • Univeristy of Colorado, Denver, CO

  • Genentech Inc., San Francisco, United States

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Nara Medical University, Kashihara, Japan

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy

Locations

  • United States

  • United Kingdom

  • Germany

  • Spain

  • South Africa

  • Switzerland

  • Japan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Blood/haematological Diseases

Disease

  • Thrombotic microangiopathy

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT02795767

  • NCT02476942

Sponsors

  • Roche Holding AG and Chugai Pharmaceutical Co.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved